Treatment-related hearing loss in weekly versus triweekly cisplatin chemoradiation for head and neck cancer.

A V M Burger C W Duinkerken Klaske E van Sluis Jan Paul de Boer Arash Navran Cornelis P Lanting Katarzyna Jóźwiak Wouter A Dreschler A J M BalmC L Zuur

Published in: European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (2024)

Cisplatin-dose reduction to a weekly cisplatin CRT regimen for head and neck cancer may reduce the incidence of clinically relevant hearing loss at frequencies vital for speech perception.

Keyphrases

hearing loss
rectal cancer
risk factors
locally advanced
combination therapy
radiation therapy
drug induced